Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F901318 (olorofim) is a novel antifungal agent belonging to the orotomide class, which inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. Posaconazole is a triazole antifungal that inhibits lanosterol 14α-demethylase (CYP51A), disrupting ergosterol synthesis in fungal cell membranes. The combination of F901318 and posaconazole has been studied for potential additive or synergistic effects against invasive fungal infections, particularly those caused by Aspergillus species and other resistant fungi. Both drugs have demonstrated efficacy in preclinical models of invasive pulmonary aspergillosis, with F901318 showing activity against azole-resistant strains[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on F901318 + posaconazole.